Apoptotic and cell cycle effects of triterpenes isolated from Phoradendron wattii on leukemia cell lines
Current antineoplastic agents present multiple disadvantages, driving an ongoing search for new and better compounds. Four lupane-type triterpenes, 3α,24-dihydroxylup-20(29)-en-28-oic acid (1), 3α,23-dihydroxy-30-oxo-lup-20(29)-en-28-oic acid (2), 3α,23-O-isopropylidenyl-3α,23-dihydroxylup-20(29)-en...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | México |
| Institución: | Centro de Investigación Científica de Yucatán |
| Repositorio: | Repositorio Institucional CICY |
| Idioma: | inglés |
| OAI Identifier: | oai:cicy.repositorioinstitucional.mx:1003/2257 |
| Acceso en línea: | http://cicy.repositorioinstitucional.mx/jspui/handle/1003/2257 |
| Access Level: | acceso abierto |
| Palabra clave: | info:eu-repo/classification/Autores/LEUKEMIA info:eu-repo/classification/Autores/LUPANE-TYPE TRITERPENE info:eu-repo/classification/Autores/APOPTOSIS info:eu-repo/classification/Autores/CELL CYCLE info:eu-repo/classification/Autores/MOLECULAR DOCKING info:eu-repo/classification/cti/2 info:eu-repo/classification/cti/24 info:eu-repo/classification/cti/2403 info:eu-repo/classification/cti/230221 |
| Sumario: | Current antineoplastic agents present multiple disadvantages, driving an ongoing search for new and better compounds. Four lupane-type triterpenes, 3α,24-dihydroxylup-20(29)-en-28-oic acid (1), 3α,23-dihydroxy-30-oxo-lup-20(29)-en-28-oic acid (2), 3α,23-O-isopropylidenyl-3α,23-dihydroxylup-20(29)-en-28-oic acid (3), and 3α,23-dihydroxylup-20(29)-en-28-oic acid (4), previously isolated from Phoradendron wattii, were evaluated on two cell lines of chronic (K562) and acute (HL60) myeloid leukemia. Compounds 1, 2, and 4 decreased cell viability and inhibit proliferation, mainly in K562, and exhibited an apoptotic effect from 24 h of treatment. Of particular interest is compound 2, which caused arrest in active phases (G2/M) of the cell cycle, as shown by in silico study of the CDK1/Cyclin B/Csk2 complex by molecular docking. This compound [3α,23-dihydroxy-30-oxo-lup-20(29)-en-28-oic acid] s a promising candidate for incorporation into cancer treatments and deserves further study. © 2022 by the authors. |
|---|